semaglutide plateau reddit IGR: New weight-loss pill beats oral Ozempic in major trial A once-daily weight-loss pill, orforglipron, has outperformed the leading oral in a major Phase 3 clinical trial involving adults with Type The FDA has approved a

Key safety concerns identified in Phase 2 data include elevated resting heart rate, gastrointestinal side effects, increased hypoglycaemia risk when combined with insulin or sulfonylureas, and class-relevant cautions around pancreatitis and thyroid C-cell tumours

Abstract Glucagon-like peptide-1 (GLP-1) has a broad spectrum of biological activity by regulating metabolic processes via both the direct activation of the class B family of G protein-coupled receptors and indirect nonreceptor-mediated pathways

Reimbursement data shows a marked increase in spending in Q3 and Q4 , likely due to more aggressive prescribing for weight loss: Q1 2024: ~$65M Q2 2024: ~$70M Q3 2024: ~$170M Q4 2024: ~$190M Unlike Ozempic, Wegovy reimbursements were more evenly distributed across dosage levels , from 0.25mg up to the full 2.4mg dose

Implications for pharma companies: Pharmas entry into the trillion-dollar club is largely driven by success in a treatment category (obesity) poised to reshape consumer health and wellness, given the massive demand for better weight loss solutions

Initial application review takes ~18-30 days, but overall credentialing, verification, and approval stretches months

With TrimRx, youll see the same commitment from day one